Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 10
2006 20
2007 34
2008 30
2009 31
2010 50
2011 70
2012 96
2013 114
2014 117
2015 134
2016 136
2017 119
2018 119
2019 148
2020 129
2021 136
2022 143
2023 160
2024 171
2025 175
2026 91

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,962 results

Results by year

Filters applied: . Clear all
Page 1
BRAF V600E in thyroid cancer: navigating prognostic uncertainty and therapeutic opportunity.
Riesco-Eizaguirre G. Riesco-Eizaguirre G. Eur Thyroid J. 2025 Dec 23;14(6):e250225. doi: 10.1530/ETJ-25-0225. Print 2025 Dec 1. Eur Thyroid J. 2025. PMID: 41368991 Free PMC article. Review.
This review explores the role of BRAF V600E in thyroid cancer with emphasis on its debated prognostic value, notable molecular heterogeneity, and opportunities as a therapeutic target. ...Moreover, due to its histology-agnostic approval for solid tumor …
This review explores the role of BRAF V600E in thyroid cancer with emphasis on its debated prognostic value, not …
BRAF(V600E) Overrides NOTCH Signaling in Thyroid Cancer.
Traversi F, Stooss A, Dettmer MS, Charles RP. Traversi F, et al. Thyroid. 2021 May;31(5):787-799. doi: 10.1089/thy.2019.0595. Epub 2020 Nov 12. Thyroid. 2021. PMID: 33012268
BRAF(V600E)-mutated PTC cell lines were resistant to pharmacological inhibition of the NOTCH pathway. ...Our findings suggest that MAP-kinase activity overrides the NOTCH pathway in the context of thyroid cancer. Conclusions: The interaction bet …
BRAF(V600E)-mutated PTC cell lines were resistant to pharmacological inhibition of the NOTCH pathway. ...Our findings s …
Preoperative BRAF(V600E) mutation detection in thyroid carcinoma by immunocytochemistry.
Swan KZ, Madsen SH, Bonnema SJ, Nielsen VE, Jespersen ML. Swan KZ, et al. APMIS. 2022 Nov;130(11):627-636. doi: 10.1111/apm.13267. Epub 2022 Aug 26. APMIS. 2022. PMID: 35951496 Free PMC article.
The BRAF(V600E) (BRAF) mutation is present in 40-50% of papillary thyroid carcinomas (PTC) and has been associated with more aggressive clinicopathological characteristics of PTC. ...These results indicate that BRAF ICC may be a feasible …
The BRAF(V600E) (BRAF) mutation is present in 40-50% of papillary thyroid carcinomas (PTC) and has been a …
Obesity Is Associated with BRAF(V600E)-Mutated Thyroid Cancer.
Rahman ST, Pandeya N, Neale RE, McLeod DSA, Bain CJ, Baade PD, Youl PH, Allison R, Leonard S, Jordan SJ. Rahman ST, et al. Thyroid. 2020 Oct;30(10):1518-1527. doi: 10.1089/thy.2019.0654. Epub 2020 May 4. Thyroid. 2020. PMID: 32228152
We used logistic regression to assess the association between body mass index (BMI) and overall thyroid cancer risk as well as by tumor BRAF mutational status as a marker of potentially higher-risk cancer. ...Conclusions: Greater risk of BRAF …
We used logistic regression to assess the association between body mass index (BMI) and overall thyroid cancer risk as well as …
A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan.
Tahara M, Kiyota N, Imai H, Takahashi S, Nishiyama A, Tamura S, Shimizu Y, Kadowaki S, Ito KI, Toyoshima M, Hirashima Y, Ueno S, Sugitani I. Tahara M, et al. Thyroid. 2024 Apr;34(4):467-476. doi: 10.1089/thy.2023.0547. Epub 2024 Mar 14. Thyroid. 2024. PMID: 38343359 Free article. Clinical Trial.
Background: Driver mutations at BRAF V600 are frequently identified in papillary thyroid cancer and anaplastic thyroid cancer (ATC), in which BRAF inhibitors have shown clinical effectiveness. ...The secondary endpoints included du …
Background: Driver mutations at BRAF V600 are frequently identified in papillary thyroid cancer and anaplastic …
BRAF V600E mutation in thyroid carcinoma: a large-scale study in Han Chinese population.
Cong R, Ouyang H, Zhou D, Li X, Xia F. Cong R, et al. World J Surg Oncol. 2024 Sep 28;22(1):259. doi: 10.1186/s12957-024-03539-7. World J Surg Oncol. 2024. PMID: 39342349 Free PMC article.
BACKGROUND: The prevalence of genetic mutations in thyroid cancer varies significantly among different ethnic backgrounds. The present study aimed to investigate the clinical potential of BRAF V600E in a large group of homogenous Han Chinese pat …
BACKGROUND: The prevalence of genetic mutations in thyroid cancer varies significantly among different ethnic backgroun …
BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma.
Lai HF, Hang JF, Kuo PC, Kuo CS, Yao SF, Chen JY, Lee CH. Lai HF, et al. Ann Surg Oncol. 2024 May;31(5):3495-3501. doi: 10.1245/s10434-024-14935-4. Epub 2024 Feb 1. Ann Surg Oncol. 2024. PMID: 38300401
BACKGROUND: Previous literatures showed wide range of prevalence of BRAF V600E in papillary thyroid carcinoma (PTC). The correlation of BRAF V600E mutation with aggressive tumor characteristics and poor prognosis is controversial. The pre …
BACKGROUND: Previous literatures showed wide range of prevalence of BRAF V600E in papillary thyroid carcinoma (PTC). Th …
THE RELATIONSHIP OF BRAF(V600E) MUTATION STATUS TO FDG PET/CT AVIDITY IN THYROID CANCER: A REVIEW AND META-ANALYSIS.
Santhanam P, Khthir R, Solnes LB, Ladenson PW. Santhanam P, et al. Endocr Pract. 2018 Jan;24(1):21-26. doi: 10.4158/EP-2017-0080. Epub 2017 Nov 16. Endocr Pract. 2018. PMID: 29144823
OBJECTIVE: Papillary thyroid cancer (PTC) harboring a BRAF(V600E) gene mutation has been shown to exhibit aggressive tumor behavior and carries higher risks of recurrence and disease-specific death. ...We included studies that compared FDG PET s …
OBJECTIVE: Papillary thyroid cancer (PTC) harboring a BRAF(V600E) gene mutation has been shown to exhibit …
BRAF mutations in thyroid cancer.
Scheffel RS, Dora JM, Maia AL. Scheffel RS, et al. Curr Opin Oncol. 2022 Jan 1;34(1):9-18. doi: 10.1097/CCO.0000000000000797. Curr Opin Oncol. 2022. PMID: 34636352 Review.
The aim of this review is to discuss the impact of BRAF mutations on clinical features and treatment of patients with thyroid cancer. RECENT FINDINGS: Despite the unfavorable course associated with PTCs harboring BRAF V600E mutation …
The aim of this review is to discuss the impact of BRAF mutations on clinical features and treatment of patients with thyro …
The BRAF(V600E) mutation analysis and risk stratification in papillary thyroid carcinoma.
Scheffel RS, de Cristo AP, Romitti M, Vargas CVF, Ceolin L, Zanella AB, Dora JM, Maia AL. Scheffel RS, et al. Arch Endocrinol Metab. 2021 May 18;64(6):751-757. doi: 10.20945/2359-3997000000285. Arch Endocrinol Metab. 2021. PMID: 34033285 Free PMC article.
OBJECTIVE: Although the prognostic role of BRAF(V600E) mutation in papillary thyroid carcinoma (PTC) is controversial, the American Thyroid Association (ATA) includes the mutational status in their risk stratification system. To evaluate …
OBJECTIVE: Although the prognostic role of BRAF(V600E) mutation in papillary thyroid carcinoma (PTC) is controve …
1,962 results